全文获取类型
收费全文 | 378285篇 |
免费 | 24856篇 |
国内免费 | 2799篇 |
专业分类
耳鼻咽喉 | 5183篇 |
儿科学 | 8205篇 |
妇产科学 | 10136篇 |
基础医学 | 53079篇 |
口腔科学 | 11776篇 |
临床医学 | 30077篇 |
内科学 | 78258篇 |
皮肤病学 | 8549篇 |
神经病学 | 27180篇 |
特种医学 | 13909篇 |
外国民族医学 | 82篇 |
外科学 | 60558篇 |
综合类 | 9957篇 |
现状与发展 | 1篇 |
一般理论 | 64篇 |
预防医学 | 17455篇 |
眼科学 | 9441篇 |
药学 | 30979篇 |
1篇 | |
中国医学 | 2193篇 |
肿瘤学 | 28857篇 |
出版年
2021年 | 2599篇 |
2019年 | 2717篇 |
2018年 | 4513篇 |
2017年 | 3427篇 |
2016年 | 3517篇 |
2015年 | 4021篇 |
2014年 | 5687篇 |
2013年 | 7378篇 |
2012年 | 10007篇 |
2011年 | 10202篇 |
2010年 | 6183篇 |
2009年 | 5840篇 |
2008年 | 9444篇 |
2007年 | 10282篇 |
2006年 | 10204篇 |
2005年 | 9262篇 |
2004年 | 8775篇 |
2003年 | 8511篇 |
2002年 | 8193篇 |
2001年 | 28279篇 |
2000年 | 28787篇 |
1999年 | 23677篇 |
1998年 | 5162篇 |
1997年 | 4253篇 |
1996年 | 3829篇 |
1995年 | 3484篇 |
1994年 | 3109篇 |
1993年 | 2844篇 |
1992年 | 16054篇 |
1991年 | 14812篇 |
1990年 | 14161篇 |
1989年 | 13965篇 |
1988年 | 12585篇 |
1987年 | 12065篇 |
1986年 | 11106篇 |
1985年 | 10324篇 |
1984年 | 6912篇 |
1983年 | 5601篇 |
1982年 | 2722篇 |
1979年 | 5484篇 |
1978年 | 3352篇 |
1977年 | 2976篇 |
1975年 | 2646篇 |
1974年 | 3068篇 |
1973年 | 2870篇 |
1972年 | 2832篇 |
1971年 | 2777篇 |
1970年 | 2517篇 |
1969年 | 2548篇 |
1968年 | 2252篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
941.
942.
F Vaylet A Bonnichon Y Salles E Gontier G Bonardel H Lefloch A Mairovitz M Mantzarides A Niang C Marotel H Foehrenbach 《Cancer radiothérapie》2007,11(1-2):16-22
Technological progress and numerous published studies allow to estimate the best place of the 18F-fluorodeoxyglucose positron emission tomography, a real functional metabolic imagery, in the clinical and therapeutic strategy of non small cell lung cancers. 相似文献
943.
Y Belkacémi B Comet J-M Hannoun-Levi S Villette H Marsiglia M Leblanc-Onfroy B Delalande D Azria J-B Dubois 《Cancer radiothérapie》2007,11(6-7):287-295
Whole breast irradiation delivering an equivalent dose of 50 Gy in 5 weeks, followed by a 10 to 16 Gy-boost to the tumor bed is the standard of care after breast-conserving surgery for early-breast cancer. Accelerated partial breast irradiation (APBI) is currently under investigations in large multi-institutional, prospective, randomized trials to objectively address the critical endpoints of treatment efficacy, toxicity and cosmesis. Patient's selection for this new approach is crucial to individualise treatments and define the subgroups of patients who will really benefit from APBI in terms of quality of life without decreasing long-term results of the disease control and cosmesis. In this review, we will discuss the patients' profiles selection for APBI regarding their general and tumor criteria. The differences between APBI techniques either performed intra or post operatively will be also discussed. 相似文献
944.
945.
Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. 总被引:1,自引:0,他引:1
Anna Orlova Fredrik Y Nilsson Maria Wikman Charles Widstr?m Stefan St?hl J?rgen Carlsson Vladimir Tolmachev 《Journal of nuclear medicine》2006,47(3):512-519
In vivo diagnosis with cancer-specific targeting agents that have optimal characteristics for imaging is an important development in treatment planning for cancer patients. Overexpression of the HER2 antigen is high in several types of carcinomas and has predictive and prognostic value, especially for breast cancer. A new type of targeting agent, the Affibody molecule, was described recently. An Affibody dimer, His6-(ZHER2:4)2 (15.4 kDa), binds to HER2 with an affinity of 3 nmol/L and might be used for the imaging of HER2 expression. The use of 99mTc might improve the availability of the labeled conjugate, and Tc(I)-carbonyl chemistry enables the site-specific labeling of the histidine tag on the Affibody molecule. The goals of the present study were to prepare 99mTc-labeled His6-(ZHER2:4)2 and to evaluate its targeting properties compared with the targeting properties of 125I-4-iodobenzoate-His6-(ZHER2:4)2 [125I-His6-(ZHER2:4)2]. METHODS: The labeling of His6-(ZHER2:4)2 with 99mTc was performed with an IsoLink kit. The specificity of 99mTc-His6-(ZHER2:4)2 binding to HER2 was evaluated in vitro with SK-OV-3 ovarian carcinoma cells. The comparative biodistributions of 99mTc-His6-(ZHER2:4)2 and 125I-His6-(ZHER2:4)2 in tumor-bearing BALB/c nu/nu mice were determined. RESULTS: The labeling yield for 99mTc-His6-(ZHER2:4)2 was approximately 60% (50 degrees C), and the radiochemical purity was greater than 97%. The conjugate was stable during storage and under histidine and cysteine challenges and demonstrated receptor-specific binding. The biodistribution study demonstrated tumor-specific uptake levels (percentage injected activity per gram of tissue [%IA/g]) of 2.6 %IA/g for 99mTc-His6-(ZHER2:4)2 and 2.3 %IA/g for 125I-His6-(ZHER2:4)2 at 4 h after injection. Both conjugates provided clear imaging of SK-OV-3 xenografts at 6 h after injection. The tumor-to-nontumor ratios were much more favorable for the radioiodinated Affibody. CONCLUSION: The use of Tc(I)-carbonyl chemistry enabled us to prepare a stable, site-specifically labeled 99mTc-His6-(ZHER2:4)2 conjugate that was able to bind to HER2-expressing cells in vitro and in vivo. The indirectly radioiodinated conjugate provided better tumor-to-liver ratios. The labeling of Affibody molecules with 99mTc should be investigated further. 相似文献
946.
N Tonami K Yokoyama J Taki K Hisada Y Watanabe T Takashima A Nonomura 《Journal of nuclear medicine》1991,32(12):2284-2285
A case of radiologically occult lung cancer is presented in which 201TI SPECT of the chest clearly delineated the involved area. A 66-yr-old man underwent chest screening examinations for asymptomatic smokers and presented a positive sputum cytology for lung cancer. Conventional chest x-ray, tomography of computed radiography, and a CT scan failed to locate the lesion in the lung. Thallium-201 SPECT, however, was successful in depicting the area of the involvement. 相似文献
947.
948.
949.
950.